Stock comparison
Jeena Sikho Lifecare Limited
JSLL.BO$71.28BHealthcare Market cap, Sector
Xeris Biopharma Holdings
XERS$1.52BHealthcare Market cap, Sector
Overall winner
Jeena Sikho Lifecare Limited
JSLL.BO 61 XERS
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
JSLL.BO6wins
1winsXERS
84B
D47
87A
B79
92A
C65
66C
B84
75B
D52
91A
C60
95A
D54
Side-by-side metrics
| Metric | JSLL.BO | XERS |
|---|---|---|
| Market cap | Winner: $71.28B | $1.52B |
| P/E (TTM) | Winner: 33.2x | 92.7x |
| EV/EBIT | Winner: 24.1x | 42.3x |
| ROIC (TTM) | Winner: 39.15% | 12.84% |
| Gross margin | Winner: 88.58% | 81.59% |
| Net margin | Winner: 27.68% | 3.81% |
| Revenue CAGR 5y | Winner: 57.81% | 55.75% |
| EPS CAGR 5y | 86.67% | - |
| Debt / Equity | Winner: 0.3x | 2.9x |
| Dividend yield | - | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
JSLL.BO leads on
- Market cap$71.28Bvs $1.52B+98%
- Debt / Equity0.3xvs 2.9x+91%
- Net margin27.68%vs 3.81%+86%
- ROIC (TTM)39.15%vs 12.84%+67%
XERS leads on
No clear edges - the other side wins or ties on every measured metric.
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.